The prognostic inhomogeneity of colorectal carcinomas stage III - A proposal for subdivision of stage III

被引:0
|
作者
Merkel, S
Mansmann, U
Papadopoulos, T
Wittekind, C
Hohenberger, W
Hermanek, P
机构
[1] Univ Erlangen Nurnberg, Dept Surg, D-91054 Erlangen, Germany
[2] Univ Heidelberg, Inst Med Biometry & Informat, D-6900 Heidelberg, Germany
[3] Univ Erlangen Nurnberg, Dept Pathol, D-8520 Erlangen, Germany
[4] Univ Leipzig, Inst Pathol, Leipzig, Germany
关键词
colorectal carcinoma; TNM classification; stage III; subdivision;
D O I
10.1002/1097-0142(20011201)92:11<2754::AID-CNCR10083>3.0.CO;2-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The prognosis of patients with Stage III colorectal carcinoma seems to be inhomogeneous. Therefore a subdivision of Stage III was performed. METHODS. Data from 850 patients of the Erlangen Registry of Colo-Rectal Carcinomas and 603 patients of the Study Group Colo-Rectal Carcinoma (SGCRC) with Stage III colorectal carcinoma were analyzed. Three different subdivisions of Stage III were performed according to pT, pN, and pTpN. Observed 5-year survival rates for all possible substages were calculated according to Kaplan-Meier. To compare the predictive value of several possible substages, Brier-Score and receiver operator charcteristics (ROC) analysis were applied. RESULTS. The subdivision according to pT (pTl,2pN1,2 versus pT3 pN1,2 versus pT4 pN1,2) as well as the subdivision according to pN (any pT pN1 vs. any pT pN2) resulted in significant differences of observed 5-year survival rates. However, subdivision according to pT and pN (pT1,2 pN1 vs. pT3,4pN1 and pT1,2pN2 vs. pT3,4 pN2) was found to be superior. The three substages, IIIA, IIIB, and IIIC, identified 10%, 50%, and 40% of the patients with observed 5-year survival rates of 80%, 60%, and 30%, respectively. Using Brier-Score and ROC analysis an increase in predictive power was found, especially for the patients of the Erlangen Registry, but less clearly for SGCRC patients. CONCLUSION. Subdivision of Stage III colorectal carcinoma into three substages according to the pT and pN categories resulted in subgroups which differed significantly in prognosis. This may be important for comparing treatment results, especially in adjuvant treatment and patient care evaluation studies. Cancer 2001; 92:2754-9. (C) 2001 American Cancer Society.
引用
收藏
页码:2754 / 2759
页数:6
相关论文
共 50 条
  • [21] Prognostic implications of chemotherapy-induced neutropenia in stage III colorectal cancer
    Kim, Sungjin
    Kang, Sung Il
    Kim, Sohyun
    Kim, Jae Hwang
    JOURNAL OF SURGICAL RESEARCH, 2021, 267 : 391 - 396
  • [22] Prognostic impact of lymph node skip metastasis in Stage III colorectal cancer
    Bao, F.
    Zhao, L. -Y.
    Balde, A. I.
    Liu, H.
    Yan, J.
    Li, T. -T.
    Chen, H.
    Li, G. -X.
    COLORECTAL DISEASE, 2016, 18 (09) : 922 - 923
  • [23] Prognostic significance of increasing lymph node count in stage III colorectal cancer
    Reddy, G. Kesava
    CLINICAL COLORECTAL CANCER, 2006, 5 (06) : 403 - 404
  • [24] Sarcopenic obesity is a postoperative prognostic factor for stage II and III colorectal cancer
    Shodai Mizuno
    Ryo Seishima
    Koji Okabayashi
    Kohei Shigeta
    Shimpei Matsui
    Yuko Kitagawa
    Journal of Gastrointestinal Surgery, 2021, 25 : 2951 - 2953
  • [25] Prognostic relevance of lymph node involvement in patients with clinical stage III ovarian carcinomas
    Krauss, T
    Osmers, R
    Meden, H
    Ravens, G
    Martin, M
    Kuhn, W
    GEBURTSHILFE UND FRAUENHEILKUNDE, 1997, 57 (06) : 349 - 352
  • [26] Connexin 43 Expression in Primary Colorectal Carcinomas in Patients with Stage III and IV Disease
    Radic, Jasna
    Kruslin, Bozo
    Samija, Mirko
    Ulamec, Monika
    Milosevic, Milan
    Jazvic, Marijana
    Samija, Ivan
    Grah, Josip Joachim
    Bolanca, Ante
    Kusic, Zvonko
    ANTICANCER RESEARCH, 2016, 36 (05) : 2189 - 2196
  • [27] CDX2 as a prognostic biomarker in stage II and stage III mismatch repair deficient colorectal cancer
    Ryan, E.
    Khaw, Y. L.
    Creavin, B.
    Geraghty, R.
    Gibbons, D.
    Sheahan, K.
    O'Connell, P. R.
    Winter, D. C.
    BRITISH JOURNAL OF SURGERY, 2017, 104 : 44 - 44
  • [28] Survival nomograms for stage III colorectal cancer
    Li, Chenglong
    Pei, Qian
    Zhu, Hong
    Tan, Fengbo
    Zhou, Zhongyi
    Zhou, Yuan
    Li, Yuqiang
    Pei, Haiping
    MEDICINE, 2018, 97 (49)
  • [29] Immunological prognostic factors in stage III melanomas
    Roberti, Maria Paula
    Jacquelot, Nicolas
    Enot, David P.
    Rusakiewicz, Sylvie
    Semeraro, Michaela
    Jegou, Sarah
    Flores, Camila
    Chen, Lieping
    Kwon, Byoung S.
    Anderson, Ana Carrizossa
    Robert, Caroline
    Borg, Christophe
    Weide, Benjamin
    Aubin, Francois
    Dalle, Stephane
    Maio, Michele
    Wolchok, Jedd D.
    Kohrt, Holbrook
    Ayyoub, Maha
    Kroemer, Guido
    Marabelle, Aurelien
    Cavalcanti, Andrea
    Eggermont, Alexander
    Zitvogel, Laurence
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [30] Bio-marker prognostic value in stage II-III of colorectal cancer
    Funaioli, Chiara
    Pinto, Carmine
    Ceccarelli, Claudio
    Mutri, Vita
    Gentile, Anna Lisa
    Limpe, Lorena Rojas
    Di Fabio, Francesca
    Longobardi, Ciro
    Martinelli, Giuseppe Nicola
    Martoni, Andrea
    ANNALS OF ONCOLOGY, 2005, 16 : 43 - 43